Cancer Therapeutics CRC researchers have developed a potential new cancer therapy that has entered clinical trials in Melbourne. The drug invented by our scientists will be taken into the first phase...
After more than a decade of successful collaboration and innovation and two rounds of Commonwealth funding through the CRC Program, today marks the final day of the Cancer Therapeutics CRC (CTx). Over...
Congratulations to the Zero Childhood Cancer personalised medicine program (ZERO), led by CRC participant, Children’s Cancer Institute (CCI), who have secured $67 million in funding from the Com...
Cancer Therapeutics CRC researchers have worked in collaboration with researchers from the Peter MacCallum Cancer Centre, the Walter and Eliza Hall Institute of Medical Research and Monash Institute f...
Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer w...
Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high...